More than 800 people at high risk for hospitalization have received antibody treatments to fight mild or moderate cases of COVID-19 since a regional infusion center opened in Mishawaka in December.
The Northern Indiana COVID Infusion Center, 60202 Bodnar Lane, offers the monoclonal antibody Bamlanivimab, produced by Lilly, and an antibody cocktail produced by Regeneron to patients who are 65 and older, or those with other risk factors such as obesity and diabetes.
Lilly chose the St. Joseph Health System site, at Elm and Jackson roads, to set up one of three regional infusion centers across Indiana in an effort to distribute antibody treatments that have received emergency approval from the FDA.